Key facts
- This page summarizes Douglas B. Given's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 May 2023, 18:29.
Douglas B. Given - 05 May 2023 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Reporting relationship
- Director
- Issuer ticker
- ARWR
- Reported as of
- 05 May 2023
- Net transaction value
- -$265,850
- SEC form
- 4
- Accepted by SEC
- 08 May 2023, 18:29:07 UTC
- Prior SEC filing
- 01 Mar 2023
- Next SEC filing
- 19 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Douglass Given
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas B. Given filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 08 May 2023.
Change
- Previous filing in this sequence was filed on 01 Mar 2023.
- Current net transaction value: -$265,850.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARWR
transaction
Common Stock
Sale
- Transaction value
- $265,850
- Shares
- -6,500
- Change %
- -5.2%
- Price
- $40.90
- Shares after
- 117,635
- Date
- 05 May 2023
- Ownership
- Direct
- Footnotes
- F1, F2
ARWR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,000
- Date
- 05 May 2023
- Ownership
- By Trust
- Footnotes
- F3
ARWR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,500
- Date
- 05 May 2023
- Ownership
- By Trust
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $40.59 to $41.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F2
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the reporting person which are subject to certain vesting conditions.
Footnote F3
Represents securities owned directly by Anne Given Trust ("AG Trust"). Douglas Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust.
Footnote F4
Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Douglas Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust.